Sodium–glucose cotransporter 2 inhibitor‐induced changes in body composition and simultaneous changes in metabolic profile: 52‐week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study

Abstract

Luseogliflozin treatment brought about favorable changes in body composition and metabolism of moderately obese Japanese type 2 diabetes patients, accompanied by body fat reduction, and minimal muscle and BMC reduction.

Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study

“…A significant reduction in uric acid levels was seen during treatment with luseogliflozin, consistent with increased urinary excretion of uric acid secondary to luseogliflozin‐induced glycosuria 48 . Taken together, the findings of the current study are consistent with the documented clinical benefits of luseogliflozin in patients with diabetes 49‐54 …”

Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans

“…In this regard, in our study, when SGLT2 inhibition was administered as an adjunct to dietary counselling, there was a greater decrease in fat-free mass (over one additional kg of lost lean tissue). Our observation is consistent with several previous studies that also report loss of fat-free mass with SGLT2 inhibition [15,38,39]. Noteworthy, in some of these studies, the duration of treatment was appreciably longer (up to 52 weeks) and the loss of fat-free mass did not become significant until week 24.…”

Update on the efficacy and safety of sodium–glucose cotransporter 2 inhibitors in Asians and non‐Asians

“…Recently, prevention of sarcopenia, which might accompany aging in patients with diabetes, has been given special attention. Luseogliflozin was found to produce beneficial changes in body composition in moderately obese Japanese type 2 diabetes patients, including body fat reduction with minimal muscle reduction, and the signs of sarcopenia were not observed after treatment. The latest edition of “recommendations” updated in July 2019 notes safety concerns, such as diabetic ketoacidosis, especially when the drug is used in type 1 diabetes patients, hypoglycemia when used with sulfonylurea or insulin, volume depletion, skin lesion and urogenital infections.…”

“…The clinical incidence of adverse reactions to tofogliflozin in patients aged ≥65 years differed little from that noted in preapproval clinical trials 12 . Recently, prevention of sarcopenia, which might accompany aging in patients with diabetes, has been given special attention 13 . Luseogliflozin was found to produce beneficial changes in body composition in moderately obese Japanese type 2 diabetes patients, including body fat reduction with minimal muscle reduction, and the signs of sarcopenia were not observed after treatment 13 .…”